As Promised -- Merck (Smallest Of The Three), Through Three Quarters Of '23... On Lobby Spending Of ~$7.2 Million.

As we said we would on Sunday, past -- we now begin to get to the other two bio-tech / pharmaceutical companies -- whose trendlines we've been tracking for well-over a decade, here. For the older deets, just search "lobby spend" in the search box, to get back to 2012, at least -- and dozens and dozens of posts, for each of these companies (though Amazon is a 2021 and later addition).

In any event, here's how modestly Merck spent its lobbying funds (only $1.8 million of the amount at right was actually spent in Q3, proper), going into a mid-term election year, in Congress:

. . .H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 Lower Costs, More Cures Act of 2021; H.R. 1550, PREVENT HPV Cancers Act of 2021; H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; H.R. 3173, Improving Seniors Timely Access to Care Act of 2021; H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021; H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021; H.R. 5260, Reduced Costs and Continued Cures Act; H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to drug pricing; H.R. 5416, Give Kids a Chance Act; H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act; H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act; H.R. 6963, Accelerated Approval Integrity Act of 2022; H.R. 7559, Prescription Information Modernization Act of 2022; H.R. 7667, Food and Drug Amendments of 2022; S. 1435, Affordable Prescriptions for Patients Act of 2021; S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019; S. 2774, Pride in Patent Ownership Act; S. 2891, Restoring the America Invents Act; S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019; S. 1895 (116th Congress) Lower Health Care Costs Act; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022

Issues relating to 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023. . . .

H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to budget reconciliation tax provisions

Issues related to, Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Tax provisions of Budget Reconciliation. . . .

Now you know. . . out, smiling -- ever. . . smiling. . . at memories of an entirely unbothered sauntering wild turkey or three, in the southern wood -- exactly eight years on, this Sunday.

नमस्ते